MiR-181a functions as an oncogene by regulating CCND1 in multiple myeloma

10Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

MicroRNA-181a (miR-181a) has been demonstrated to be upregulated in patients with multiple myeloma (MM). In several studies, miR-181a has been demonstrated to be significantly overexpressed in MM; however, its potential role in development and progression of MM remains unknown. In the present study, the functions of miR-181a and the potential underlying molecular mechanisms in the pathogenesis of MM were examined. Increased expression of miR-181a was observed in bone marrow samples from patients with MM and the MM RPMI8226 cell line. The role of miR-181a was examined and it was demonstrated that it participated in the proliferation and migration processes of the MM cell line. Furthermore, it was demonstrated that the downregulation of miR-181a inhibited the expression of CCND1, a cell cycle regulatory gene, and caused cell cycle arrest in MM cells. The results of the present study suggested that miR-181a functions as an onco-miRNA in MM, which serves regulatory roles by upregulating expression of CCND1 and may therefore serve as a potential target in patients with MM.

Cite

CITATION STYLE

APA

Yan, X., Gao, M., Zhang, P., Ouyang, G., Mu, Q., & Xu, K. (2020). MiR-181a functions as an oncogene by regulating CCND1 in multiple myeloma. Oncology Letters, 20(1), 758–764. https://doi.org/10.3892/ol.2020.11579

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free